Oxford Biomedica plc (OXB) Ordinary 50p

Sell:317.00pBuy:327.50p4.00p (1.25%)

FTSE techMARK 100:0.01%
Market closed | Prices delayed by at least 15 minutes
Sell:317.00p
Buy:327.50p
Change:4.00p (1.25%)
Market closed | Prices delayed by at least 15 minutes
Sell:317.00p
Buy:327.50p
Change:4.00p (1.25%)
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

Oxford Biomedica PLC is a contract development and manufacturing organization (CDMO) in cell and gene therapy. The Company is engaged in providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. It offers a number of technologies for viral vector manufacturing, including a fourth-generation lentiviral vector system (the TetraVecta system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. Its LentiVector platform technology is an advanced lentiviral vector-based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. Its AAV platform, which offers a proprietary plug and play dual-plasmid system for transient transfection, as well as a standard triple transfection system for AAV-based gene therapies.

Key people

Frank Mathias
Chief Executive Officer, Executive Director
Lucinda Crabtree
Chief Financial Officer, Executive Director
Thierry Cournez
Chief Operating Officer, Site Head of UK Operations
Lisa Doman
Chief People Officer
Natalie Walter
Group General Counsel, Company Secretary
Kyriacos Mitrophanous
Chief Innovation Officer
Sebastien Ribault
Chief Business Officer
Sabine Sydow
Chief Of Staf
Roch Frederic Doliveux
Independent Non-Executive Chairman of the Board
Colin Bond
Independent Non-Executive Director
Laurence Espinasse
Non-Executive Director
Robert Ghenchev
Non-Executive Director
Dame Kay Davies
Senior Independent Non-Executive Director
Click to see more

Key facts

  • EPIC
    OXB
  • Location
    United Kingdom
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    GB00BDFBVT43
  • Market cap
    £335.25m
  • Employees
    861
  • Shares in issue
    106.13m
  • Exchange
    London Stock Exchange (LON)
  • Index
    FTSE All Share Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.